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ABSTRACT 
Strategies to enhance tumor immunogenicity may expand the role of immunotherapy beyond the 
mismatch repair-deficient subtype. In this pilot study, biopsies were performed at baseline and after 
four cycles of FOLFOX in eight patients receiving neoadjuvant chemotherapy for stage II/III locally 
advanced rectal cancer.  Immunostaining was performed for T cell subsets (CD3+, CD8+, CD45RO+); 
macrophages (CD163+); T regulatory cells (FOXP3+); and expression of MHC class I, PD-1 and PD-L1. 
Changes in cell number or intensity were quantified and correlated with treatment response. 
Pretreatment patterns of immune infiltrates were mixed and did not correlate with treatment 
response. Posttreatment increases in T cell infiltrates (CD3+, CD8+ and CD45RO+) and MHC-I 
expression were observed in five patients.  CD163+ cell numbers increased in four patients.  FOXP3+ 
cells numbers increased in two patients, decreased in two other patients and remained unchanged 
in three patients. PD-1 scores increased in seven patients, and PD-L1 scores increased in four 
patients. Changes in tumor T cell responses did not correlate with treatment response.  Changes in 
FOXP3+ cells were associated with treatment response in some patients: two patients with increases 
in FOXP3+ cells had poor responses, whereas the patient with the greatest reduction in FOXP3+ cells 
had a complete response. The patient with a complete clinical response had a much higher increase 
in MHC-I expression than other patients.  These results suggest that chemotherapy can increase 
immune activity in the tumor microenvironment and could potentially be utilized to prime immune 
responses prior to immunomodulatory treatments. 
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Introduction 
Immunotherapies have become routine in treatment of various cancers, such as melanoma, where 
checkpoint blockade of CTLA-4 and PD-1 T-cell inhibitory molecules helps lengthen progression-free 
survival and overall survival.1  T-cell regulatory (Treg) receptor PD-1 and its ligand PD-L1 are 
expressed in most cancers,2 and together they can dampen the antitumor immune response.  
Tumors thought to be susceptible to anti-PD-1 include those with high mutational load and 
neoantigen burden 3 or with evidence of an immune-active tumor microenvironment (CD3/CD8+ 
infiltrates and MHC class I expression).4,5  Intratumoral PD-1/PD-L1 expression and presence of T 
cells within the tumor microenvironment  are thought to represent the most useful indicator that 
anti- PD-1 therapy may be effective.  
 
To date, the role of immunotherapy in colorectal cancer (CRC) has been limited to the mismatch 
repair-deficient (dMMR) subtype.  dMMR tumors are strongly immunogenic, with high numbers of 
tumor-infiltrating lymphocytes thought to be responding to neoantigens brought about by the high 
mutational burden.6  Compared with mismatch repair-proficient (pMMR) CRC, dMMR tumors also 
express higher levels PD-1/PD-L1.7,8 Phase II trials have shown that anti-PD-1/PD-L1 agents help 
lengthen progression-free and overall survival in patients with stage IV dMMR CRC.9,10  However, 
since dMMR tumors account for only 25%, 12% and 4% of stage II, III and IV CRCs, respectively, 
immunotherapy is a treatment option in only a small subset of CRCs.  
 
The majority of pMMR CRCs exhibit low numbers of T cells in the tumor microenvironment, along 
with low levels of PD-1/PD-L1 expression; therefore, checkpoint blockade immunotherapy is not 
thought to be effective.11 Strategies aimed at enhancing immunogenicity in pMMR CRC may allow 
broader use of immunotherapy. Along this line of reasoning, conventional cytotoxic chemotherapy 
and radiotherapy (RT) are thought to result in immunogenic cell death, with T cell infiltrates 
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responding to release of antigen from damaged cells.12  Such treatments may synergize with 
immunotherapies, enhancing treatment response. Trials are currently under way employing 
combinations of immunotherapies with immune-priming strategies in gastroesophageal, head and 
neck, and lung cancers (NCT02872116, NCT02764593 and NCT02944396 on 
www.ClinicalTrials.gov).13   
 
Observational data suggest that RT enhances T cell infiltration in locally advanced rectal cancer, and 
preclinical models suggest that cytotoxic chemotherapy may have similar effects.14-18  However, the 
effect of cytotoxic chemotherapy on intratumoral immune responses in patients with CRC has not 
previously been studied. In this prospective pilot study, we investigated whether conventional 
cytotoxic chemotherapy can induce immune priming in pMMR locally advanced rectal cancer.  
 
 
Results 
Matched biopsies taken before and after four cycles of induction FOLFOX chemotherapy (folinic acid, 
fluorouracil and oxaliplatin) were collected in eight patients: six men and two women, ages 33-78 
years.  The clinical and pathological characteristics of the cohort are listed in Table 1.  All eight 
patients had clinical stage III (node-positive) disease; two had cT4 tumors, five had cT3 tumors, and 
one had a cT2 tumor.  The distance of the tumor from the anal verge was <5 cm in three patients, 5-
10 cm in three other patients and >10 cm in two patients.   
 
Pretreatment MMR status was available for seven patients; all seven had retained expression of 
MMR proteins. The number of days between the index biopsy and completion of four cycles of 
FOLFOX ranged from 61 to 127 days (mean 82 days).  By the completion of neoadjuvant treatment, 
six patients had downstaging of T stage and all eight patients had downstaging of N stage.  Two 
5 
 
patients had a poor clinical response, five patients had an incomplete response, and one patient had 
a complete response, based on digital exam, endoscopy and MRI.  
 
The data on pre- and posttreatment tumor immune responses are shown in Table 2 and Figure 1.  
Pretreatment patterns of immune infiltrates were mixed and did not appear to correlate with 
responses to treatment.  CD3+ and CD8+ infiltrates increased in five patients, CD45RO+ infiltrates 
increased in four patients, and CD163+ cells increased in four patients.  The MHC-I histoscore 
increased in five patients, the PD-1 score increased in seven patients, and the PD-L1 score increased 
in four patients.  FOXP3+ infiltrates increased in two patients, decreased in two other patients and 
remained unchanged in three patients (pretreatment FOXP3+ data was not available for one of the 
eight patients). The two patients with increases in FOXP3+ cells had poor responses to treatment, 
whereas the patient with the greatest reduction in FOXP3+ cells had a complete clinical response 
(Fig. 2). The patient with a complete response had a much higher increase in MHC-I expression 
within the tumor than the other patients.  
 
Discussion 
The findings of our pilot study suggest that FOLFOX chemotherapy is capable of inducing changes in 
the immune contexture within the tumor microenvironment, such as increases in T cells (CD3+, 
CD8+ and CD45RO+) and in MHC-I and PD-1 expression.  These changes are similar to those 
observed in preclinical models after chemoradiotherapy (CRT) secondary to immunogenic cell death 
with antigen release, increased MHC-I and cross-presentation to T cells.15-19 In rectal cancer patients 
treated with CRT, higher numbers of CD4+/CD8+ cells in resected specimens than in pretreatment 
biopsies have been reported.14,20  CRT also induces systemic immune changes, including reductions 
in circulating Tregs and myeloid-derived suppressor cells.21  This immunomodulation may account 
for the reported abscopal effects on distant metastases after RT to the primary tumor, potentially 
mediated by cross-priming of T cells following tumor cell death.12, 18,19  
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Our results are consistent with previous reports of association between changes in Tregs and 
treatment response. We observed that tumors in which FOXP3+ Tregs increased had a poor 
treatment response.  The role of Tregs in CRC is not clear, but they are known to harbor 
immunosuppressive activity, dampening T cell responses.22  Low numbers of FOXP3+ Tregs in 
posttreatment resection specimens have been reported to be associated with greater treatment 
response after CRT.23 No strong relationship between pretreatment Tregs and treatment response 
has been observed, suggesting that the type of immune response generated by RT is more 
important.24   
 
The patient with a complete clinical response had the largest increase in MHC-I expression.  High 
MHC-I expression reflects increased antigen presentation and is considered a measure of an 
immune-active microenvironment; it may therefore indicate ongoing immunogenic cell death in 
response to FOLFOX.  Further work is required to test this hypothesis and to determine whether 
MHC-I has potential as an early biomarker of response during chemotherapy treatment.  
 
We found no appreciable relationship between T cell changes and treatment response, even for 
tumors with a 200% increase in T cell numbers.  Further work is required to determine whether the 
effects of these T cell responses are mitigated by the presence of inhibitory immune checkpoints 
(e.g., PD-1 and CTLA-4) or other T cell suppressors (myeloid-derived suppressor cells or Tregs). 
 
No biomarkers of response to immunotherapies (e.g., anti-CTLA-4 and anti-PD-1/ PDL1) are 
available, but pretreatment evidence of an immune-active tumor microenvironment (e.g., high T 
cells and MHC-I expression) is considered important.3-5 Where such features are absent, strategies to 
prime the microenvironment in order to induce immune responses are sought.  FOLFOX may be 
capable of achieving these desirable effects in a proportion of patients.  Sequencing of 
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chemotherapy and RT to optimize immunological sequelae is likely to be critical to successful 
utilization of immunotherapy and requires further investigation. The relative ease with which tumor 
biopsies were collected from outpatients in our study indicates that rectal tumors are ideal for 
studying the scheduling of priming treatments.  
 
In summary, the results of our pilot study indicate that FOLFOX chemotherapy in patients with 
locally advanced rectal cancer was associated with increases in T cell infiltrates, MHC-I expression 
and PD-1 expression.  It is likely that the immunogenicity generated in response to chemotherapy 
plays a role in treatment response, and evidence of this role may be more apparent in a larger study.  
Our findings suggest that neoadjuvant chemotherapy can potentially be utilized to prime immune 
responses prior to immunomodulatory treatments.  These observations provide support for ongoing 
work investigating the role of immune stimulation by conventional treatments in rectal cancer and 
for future trials aimed at evaluating combinations of chemotherapy, RT, and immunotherapy.   
 
Patients and Methods    
Patients 
The study population consisted of nonconsecutive patients seen over a 4-month period with locally 
advanced rectal cancer clinically staged cT3/4 or N+ (American Joint Committee on Cancer stage II 
and III) who received neoadjuvant therapy prior to planned rectal resection. As per National 
Comprehensive Cancer Network guidelines, the patients received eight cycles of induction FOLFOX 
prior to CRT.25  With approval from the institutional review board, we prospectively evaluated the 
immune contexture of tumor biopsies taken at baseline and after four cycles of FOLFOX 
chemotherapy.  All patients were considered to have pMMR tumors based on pretreatment biopsy 
immunohistochemistry (no loss of MLH1, PMS2, MSH2 or MSH6 protein expression).   
 
Samples 
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Immunohistochemistry was performed on matched samples (biopsy at initial diagnosis and after 
four cycles of FOLFOX) to grade infiltrates of T cells (CD3+, CD8+, CD45RO+), Tregs (FOXP3+) and 
macrophages (CD163+) (Fig. 3).  We also evaluated MHC-I (as a measure of antigen presentation) 
and PD-1/PDL-1 expression. Sections of 4-μm thickness were obtained from paraffin-embedded 
biopsy samples.  After deparaffinization and rehydration, sections were incubated with primary 
monoclonal antibodies recognizing CD3 (LN10, 1:100; Leica Biosystems), CD8 (SP57, ready to use; 
Ventana), CD45RO (UCHL1, 1:200; Dako), FOXP3 (236A/E7, 1:500; Abcam), CD163 (MRQ-26, ready to 
use; Cell Marque), MHC-I (A4; Thermo Fisher Scientific), PD-1 (NAT105, ready to use; Cell Marque), 
or PD-L1 (E1L3N, 1:250; Cell Signaling Technology). We used the staining platforms BenchMark Ultra 
from Roche (CD3 and CD163) and BenchMark Ultra from Ventana (CD8) and the detection systems 
OptiView from Ventana (CD3, CD8, CD163 and PD-1) and Bond Polymer Refine from Leica 
Biosystems (CD45RO, FOXP3, MHC-I and PD-L1).  
 
Immune response  
Immune cells expressing CD3+, CD8+, CD45RO+, FOXP3+ or CD163+ were quantified in biopsy 
specimens using a cell counting approach.  For each specimen, three high-power fields containing 
both tumor stroma and epithelium were selected at random. Cell counts were averaged over the 
three fields.  MHC-I expression was assigned a modified histoscore obtained by multiplying the 
percentage of cells expressing MHC-I by the intensity of staining, which was graded on a scale of 0 to 
3. Histoscore values therefore ranged from 0 to 300.  PD-1 and PD-L1 were assessed using a 
previously described method.26  Briefly, tumor cells staining for PD-L1 and tumor-infiltrating 
lymphocytes expressing PD-1 were graded on a scale from 0 to 2 (0, no staining; 1+, faint or weak 
staining; 2+, moderate or strong staining).  Increases or decreases of >25% in absolute cell counts or 
antibody staining intensity, in addition to any point change in the PD-1/PD-L1 scores (0-2) in 
posttreatment samples, were categorized as changes in the immune response.  C.R. scored all the 
slides, with dual scoring for three patients by J.S. to ensure consistency. 
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Staging and clinical response 
Pretreatment staging was based on MRI data. Posttreatment staging was based on MRI/CT data in 
patients with a complete clinical response or on resection specimen pathology in patients 
undergoing surgery.  A downward posttreatment change in T or N stage (e.g., T4 to T3 or N1 to N0) 
was categorized as downstaging.  Complete clinical response was defined as absence of clinical, 
endoscopic or radiographic evidence of tumor at completion of neoadjuvant therapy. At Memorial 
Sloan Kettering, such patients are offered the option of nonoperative, watch-and-wait management. 
A reduction of <50% in tumor bulk was categorized as poor response, and a reduction of 50-99% was 
categorized as a good but incomplete response. 
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Figure 1. Tumor microenvironment changes in counts of immune cells and expression of MHC-1, PD-
1 and PDL-1 that occurred during FOLFOX treatment. Complete, good, and incomplete responses to 
treatment are indicated by light grey, dark grey, and black lines, respectively. hpf, high-power field. 
 
Figure 2.  Immune responses in relation to treatment responses. The PD-1 score did not change for 
one patient with a good response; the PD-L1 score did not change for one patient with a poor 
response. 
 
Figure 3.  Representative micrographs of immunostaining for antibody expression in rectal cancer 
biopsies. Scale bars: 500 µm for FOXP3+, 1 mm for all others.    
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Table 1. Clinical and pathological characteristics of the study cohort. 
Patient 
Age 
(yr) 
Sex 
Initial MRI 
Stage 
Distance from 
Anal Verge (cm) 
Days between 
Biopsiesa 
Posttreatment 
Stage 
Downstaging Complete 
Response T  N  
1 63 M cT4b N1 7.6 82 ypT1 N0 Yes Yes No 
2 69 M cT3c N1 5.0 62 ypT2 N0 Yes Yes No 
3 67 F cT4b N1 3.2 81 ypT2 N0 Yes Yes No 
4 75 M cT2 N1 6.5 89 ycT0 N0 Yes Yes Yes 
5 34 M cT3c N2 13.0 78 ypT3 N1 No Yes No 
6 78 M cT3b N1 2.8 127 ypT2 N0 Yes Yes No 
7 48 F cT3b N2 5.8 61 ypT3 N1 No Yes No 
8 33 M cT3b N1 12.0 74 ypT2 N0 Yes Yes No 
aAll patients had received four cycles of FOLFOX by the time of the second biopsy. 
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Table 2.  Pre- and posttreatment immune responses.a  
 
Biopsy 
Cells/HPF MHC-I 
Histoscore 
PD-1 
Score 
PD-L1 
Score 
CD3+  CD8+ CD45RO+  FOXP3+ CD163+ 
Patient 1         
Pre 23 22 20 10 22 220 1 2+ 
Post 5 5 7  6 10 280 2+ 1+ 
         
Patient 2         
Pre 13 6 17  8 10 175 1+ 0 
Post 21 18 29  7 16 270 1+ 1+ 
         
Patient 3         
Pre 14 12 22 10 10 200 0 1+ 
Post 19 17 26 12 15 230 1+ 0 
         
Patient 4         
Pre 15 8 16 17 15   45 0 0 
Post 25 14 23  5 14 210 1+ 1+ 
         
Patient 5         
Pre 9 3 15  5 11 180 0 0 
Post 14 9 22  8 16 230 1+ 1+ 
         
Patient 6         
Pre 21 15 22 NA 15 210 1+ 1+ 
Post 22 7 23  5 14 125 2+   0 
         
Patient 7         
Pre 20 8 15  8 12 220 0 0 
Post 10 9 20 14 14 210 1+ 0 
         
Patient 8         
Pre 8 5 17  5 9 155 0 0 
Post 22 12 15  4 14 405 1+ 1+ 
aIncreases of >25% are boldfaced. Decreases of >25% are italicized. HPF, high-power field; NA, not 
available. 
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